

David M Loeb

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5898463/david-m-loeb-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

893
citations

16
h-index

29
g-index

47
ext. papers

1,130
ext. citations

4.4
avg, IF

4.12
L-index

#	Paper	IF	Citations
46	Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave.. <i>Cancer Cell</i> , 2022 ,	24.3	1
45	Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.. <i>Cancer Immunology, Immunotherapy</i> , 2022 ,	7.4	1
44	Pembrolizumab as maintenance therapy for malignant rhabdoid tumor.. <i>Pediatric Blood and Cancer</i> , 2022 , e29660	3	
43	SARS-CoV-2 as a mimicker of pulmonary metastasis in osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2021 , e29435	3	0
42	Respiratory Failure in a Child With Pulmonary Metastatic Osteosarcoma and COVID-19. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e859-e860	1.2	5
41	Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11577-TPS11577	2.2	1
40	Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11514-11514	2.2	1
39	Delayed presentations of pediatric solid tumors at a tertiary care hospital in the Bronx due to COVID-19. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28615	3	12
38	Circulating Plasma Tumor DNA Is Superior to Plasma Tumor RNA Detection in Ewing Sarcoma Patients: ptDNA and ptRNA in Ewing Sarcoma. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 872-881	5.1	0
37	XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IκB. <i>Translational Oncology</i> , 2021 , 14, 101114	4.9	4
36	Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28370	3	6
35	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020 , 2020, 7935475	3.1	9
34	An evolutionary framework for treating pediatric sarcomas. <i>Cancer</i> , 2020 , 126, 2577-2587	6.4	7
33	A clinically and genomically annotated nerve sheath tumor biospecimen repository. <i>Scientific Data</i> , 2020 , 7, 184	8.2	6
32	Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma. <i>Translational Oncology</i> , 2020 , 13, 100809	4.9	7
31	Wnt Signaling in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1258, 125-139	3.6	11
30	Enolate-forming compounds provide protection from platinum neurotoxicity. <i>Chemico-Biological Interactions</i> , 2020 , 317, 108961	5	0

29	Consensus and controversies regarding the treatment of rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26809	3	42
28	Knock-in of the R394W mutation causes MDS and cooperates with to drive aggressive myeloid neoplasms in mice. <i>Oncotarget</i> , 2018 , 9, 35313-35326	3.3	4
27	Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition. <i>Cell Death and Disease</i> , 2018 , 9, 1161	9.8	5
26	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. <i>Clinical Sarcoma Research</i> , 2018 , 8, 21	2.5	13
25	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2040-2046	4.7	18
24	Treatment pathway of bone sarcoma in children, adolescents, and young adults. <i>Cancer</i> , 2017 , 123, 220662218	2.18	89
23	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017 , 8, 41-55	2.7	8
22	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. <i>International Journal of Cancer</i> , 2017 , 141, 1469-1477	7.5	31
21	Size-based detection of sarcoma circulating tumor cells and cell clusters. <i>Oncotarget</i> , 2017 , 8, 78965-78973	3.7	28
20	Induction of Immune Response after Allogeneic WilmsTumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2149-2154	4.7	28
19	A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. <i>Oncotarget</i> , 2016 , 7, 21114-23	3.3	47
18	SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. <i>Cancer</i> , 2016 , 122, 868-74	6.4	61
17	Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. <i>Cancer</i> , 2016 , 122, 3015-23	6.4	44
16	Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma. <i>British Journal of Cancer</i> , 2015 , 113, 894-901	8.7	4
15	Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells. <i>PLoS ONE</i> , 2015 , 10, e0119837	3.7	47
14	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. <i>PLoS ONE</i> , 2015 , 10, e0133152	3.7	56
13	Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1033-9	4.7	16
12	Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1000-7	4.7	8

11	Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. <i>PLoS Genetics</i> , 2014 , 10, e1004107	6	26
10	Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012 , 120, 4205-4205	2.2	1
9	Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012 , 120, 4206-4206	2.2	
8	WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. <i>Journal of Biological Chemistry</i> , 2011 , 286, 43634-43643	5.4	46
7	Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. <i>Blood</i> , 2011 , 118, 2437-2437	2.2	22
6	High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. <i>PLoS ONE</i> , 2010 , 5, e13943	3.7	113
5	Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. <i>Cancer</i> , 2010 , 116, 5470-8	6.4	26
4	Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. <i>Cancer</i> , 2009 , 115, 2514-22	6.4	49
3	Identification of Alternative Splicing Events Regulated by the BCR-ABL Oncoprotein. <i>Blood</i> , 2008 , 112, 3206-3206	2.2	
2	What is the optimal therapy for childhood AML?. <i>Oncology</i> , 2002 , 16, 1057-66; discussion 1066, 1068-70	1.8	1
1	Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. <i>Medical and Pediatric Oncology</i> , 2001 , 37, 365-71		11